Eli Lilly said a mid-stage trial of a treatment for rheumatoid arthritis met its main goal for efficacy. The pharma giant published detailed results from a phase 2a trial of peresolimab in the New England Journal of Medicine. (Seeking Alpha)
Eyepoint Pharmaceuticals agreed to sell Yutiq to Alimera Sciences for $82.5 million. Alimera will receive global rights to Yutiq outside of China, Hong Kong, Taiwan, Macau, and Southeast Asia, where Yutiq is exclusively licensed to Ocumension Therapeutics, and EyePoint will continue to receive royalties from Ocumension for its Yutiq sales. (Benzinga)
A Midwest anti-abortion group used cellphone location data to target online content to visitors of certain Planned Parenthood clinics. The Wisconsin group used precise geolocation data until last year to direct ads to women it suspected of seeking abortions. (The Wall Street Journal)
Almost half of the children on Ozempic are no longer clinically obese, a landmark study found. One hundred and thirty-four of these children received a weekly dose of 2.4 milligrams of semaglutide for more than a year, alongside healthy lifestyle counseling. (Insider)
As drug shortages near an all-time high, cancer patients have resorted to rationing. A worrisome scarcity of cancer drugs has heightened concerns about the troubled generic drug industry. Congress and the White House are seeking ways to address widespread supply problems. (The New York Times)
